Faculty profile

Rena Buckstein

Back to faculty

Associate ProfessorDepartment of MedicineUniversity of Toronto

Rena Buckstein

Associate Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
7 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2011.
Supervisor on 1 trainee award (1 CIHR), most recently in 2011.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

519

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?
Haematologica · 2026 · senior author
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.
Hepatology communications · 2025
A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.
Blood advances · 2024

All 30 publications

Latest funding

Myelodysplastic Syndromes (MDS) in Canada: A national prospective study of the epidemiology, quality of life and impact of co-morbidity/frailty on disease outcome
CIHR · 2011 · Nominated PI
$100,000
Safety and Efficacy of a Therapeutic Platelet Transfusion Strategy in Outpatients
CIHR · 2011 · Co-investigator
$150,031
Phase II trial of Azacitidine plus Deferasirox in higher risk Myelodysplastic Syndromes (MDS)
CIHR · 2011 · Supervisor
$27,500

All 3 grants and awards

30 publications.

Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?

Mozessohn L, Buckstein R

Haematologica2026Senior authorOpen Access

DOI: 10.3324/haematol.2025.288157 PMID: 40568724

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.

Tabataba Vakili S, Hirode G, Zahoor A, Saunthar A, Feld JB, Hansen BE, Syeda A, Janssen HLA, Kukreti V, Kuruvilla J, Prica A, Cheung M, Buckstein R, Hicks L, Coffin CS, Street LE, Disperati P, Chan KK, Crump M, Feld JJ

Hepatology communications20252 citationsOpen Access

DOI: 10.1097/hc9.0000000000000859 PMID: 41335575

A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.

Ravindran M, Mozessohn L, Cheung M, Buckstein R, Teichman J

Blood advances20245 citationsOpen Access

DOI: 10.1182/bloodadvances.2023011219 PMID: 38029373

The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry

Buckstein R, Chodirker L, Yee KWL, Geddes M, Leitch HA, Christou G, Banerji V, Leber B, Khalaf D, St-Hilaire E

Leukemia and Lymphoma202314 citationsFirst authorOpen Access

DOI: 10.1080/10428194.2022.2156793

Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes

Mozessohn L, Li Q, Liu N, Leber B, Khalaf D, Sabloff M, Christou G, Yee K, Chodirker L, Parmentier A

JCO Oncology Practice20236 citationsSenior authorOpen Access

DOI: 10.1200/op.22.00668

A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features

Christina K. Ferrone, Amy J. M. McNaughton, Iran Rashedi, Brooke A. Ring, Rena J. Buckstein, Hubert Tsui, Michael J. Rauh

Modern Pathology20233 citationsOpen Access

DOI: 10.1016/j.modpat.2022.100068 PMID: 36788103

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.

Buckstein R, Chodirker L, Mozessohn L, Yee KWL, Geddes M, Zhu N, Shamy A, Leitch HA, Christou G, Banerji V, Brian L, Khalaf D, St-Hilaire E, Finn N, Nevill T, Keating MM, Storring J, Delage R, Parmentier A, Thambipillai A, Siddiqui M, Westcott C, Cameron C, Mamedov A, Spin P, Tang D

Leukemia & lymphoma20226 citationsFirst authorOpen Access

DOI: 10.1080/10428194.2022.2109154 PMID: 36095125

Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia.

Mozessohn L, Cheung MC, Mittmann N, Earle CC, Liu N, Buckstein R

JCO oncology practice20218 citationsSenior author

DOI: 10.1200/op.20.00446 PMID: 32956005

Predictors of intensive care unit admission in patients with hematologic malignancy.

Vijenthira A, Chiu N, Jacobson D, Freedman Z, Cheung MC, Goddard S, Fowler R, Buckstein R

Scientific reports202036 citationsSenior authorOpen Access

DOI: 10.1038/s41598-020-78114-7 PMID: 33273653

Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'.

Mozessohn L, Cheung MC, Mittmann N, Earle CC, Liu N, Buckstein R

Leukemia & lymphoma20208 citationsSenior author

DOI: 10.1080/10428194.2020.1723012 PMID: 32036719

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Rena Buckstein

Research

Latest papers

Latest funding

Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?

Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial.

A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML.

The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry

Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes

A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features

A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.

Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia.

Predictors of intensive care unit admission in patients with hematologic malignancy.

Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'.

Myelodysplastic Syndromes (MDS) in Canada: A national prospective study of the epidemiology, quality of life and impact of co-morbidity/frailty on disease outcome

Safety and Efficacy of a Therapeutic Platelet Transfusion Strategy in Outpatients

Phase II trial of Azacitidine plus Deferasirox in higher risk Myelodysplastic Syndromes (MDS)

Frequent collaborators

Matthew Cheung

Lee Mozessohn

Lisa Chodirker

David Spaner

Kevin Imrie

Anca Prica

Ning Liu

Brian Leber

Nicole Mittmann

Michael Crump

Neil Berinstein

Yulia Lin

Versha Banerji

John Kuruvilla

Zeina Ghorab

Vikas Gupta

Jennifer Teichman

Eric Tseng

Abi Vijenthira

Carla Coffin

George Tomlinson

Mark Minden

Madeline Li

Annette Hay

Donald Arnold

Jeannie Callum

Bettina Hansen